Retraction notice to "Prognostic factors for the long-term survival in patients with vasospastic angina-Analysis of effects of patients' characteristics and therapeutic drugs" [J. Cardiol. 54 (2009) 10-20] (DOI:10.1016/j.jjcc.2009.02.013);Prognostic factors for the long-term survival in patients with vasospastic angina. Analysis of effects of patients' characteristics and therapeutic drugs

Journal of Cardiology

Volumn 54, Issue 1, 2009, Pages 10-20

  Kodama, Sunao ^a   Inoue, Yukiko ^a   Mihara, Hiroyuki ^a   Sumi, Syunichiro ^a   Kudo, Keiko ^a   Okamura, Keisuke ^a   Ando, Chie ^a   Niimura, Hideya ^a   Tsuchiya, Yoshihiro ^a   Yamanouchi, Yoshio ^a   Urata, Hidenori ^a  

^a Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Benidipine; Long term survival; Vasospastic angina

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BENIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DILTIAZEM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NIFEDIPINE; NITRATE;

ADULT; AGE; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL FEATURE; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY SPASM; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME;

AGED; ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; CORONARY VASOSPASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 67650763172     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.12.004     Document Type: Erratum

References (33)

1. Yasue H., Nakagawa H., Itoh T., Harata E., and Mizuno Y. Coronary artery spasm-clinical features, diagnosis, pathogenesis, and treatment. J Cardiol 51 (2008) 2-17
2. Vanhotte P.M., and Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 80 (1989) 1-9
3. Kugiyama K., Yasue H., Okumura K., Ogawa H., Fujimoto K., Nakao K., Yoshimura M., Motoyama T., Inobe Y., and Kawano H. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 94 (1996) 266-271
4. Pristipino C., Beltrame J.F., Finocchiaro M.L., Hattori R., Fujita M., Mongiardo R., Cianflone D., Sanna T., Sasayama S., and Maseri A. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 101 (2000) 1102-1108
5. Sueda S., Kohno H., Fukuda H., Ochi N., Kawada H., Hayashi Y., and Uraoka T. Frequency of provoked coronary spasms in patients undergoing coronary arteriography using a spasm provocation test via intracoronary administration of ergonovine. Angiology 55 (2004) 403-411
6. Sueda S., Ochi N., Kawada H., Matsuda S., Hayashi Y., Tsuruoka T., and Uraoka T. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol 83 (1999) 1186-1190
7. Kawano H., and Ogawa H. Endothelial dysfunction and coronary artery spasm. Curr Drug Targets Cardiovasc Haematol Disord 4 (2004) 23-33
8. Nakayama M., Yasue H., Yoshimura M., Shimasaki Y., Kugiyama K., Ogawa H., Motoyama T., Saito Y., Ogawa Y., Miyamoto Y., and Nakao K. T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99 (1999) 2864-2870
9. Yoshimura M., Yasue H., Nakayama M., Shimasaki Y., Sumida H., Sugiyama S., Kugiyama K., Ogawa H., Ogawa Y., Saito Y., Miyamoto Y., and Nakao K. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103 (1998) 65-69
10. Yoshimura M., Yasue H., Nakayama M., Shimasaki Y., Ogawa H., Kugiyama K., Saito Y., Miyamoto Y., Ogawa Y., Kaneshige T., Hiramatsu H., Yoshioka T., Kamitani S., Teraoka H., and Nakao K. Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T-786-->C and missense Glu298Asp variants. J Investig Med 48 (2000) 367-374
11. Nakayama M., Yoshimura M., Sakamoto T., Abe K., Yamamuro M., Shono M., Suzuki S., Nishijima T., Miyamoto Y., Saito Y., Nakao K., Yasue H., and Ogawa H. A-786T>C polymorphism in the endothelial nitric oxide synthase gene reduces serum nitrite/nitrate levels from the heart due to an intracoronary injection of acetylcholine. Pharmacogenet Genomics 16 (2006) 339-345
12. Yasue H., Takizawa A., Nagao M., Nishida S., Horie M., Kubota J., Omote S., Takaoka K., and Okumura K. Long-term prognosis for patients with variant angina and influential factors. Circulation 78 (1988) 1-9
13. Nakamura M., Takeshita A., and Nose Y. Clinical characteristics associated with myocardial infarction, arrhythmias, and sudden death in patients with vasospastic angina. Circulation 75 (1987) 1110-1116
14. Ito A., Fukumoto Y., and Shimokawa H. Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol 44 (2004) 480-485
15. Sueda S., Kohno H., Fukuda H., Watanabe K., Ochi N., Kawano H., and Uraoka T. Limitations of medical therapy in patients with pure coronary spastic angina. Chest 123 (2003) 380-386
16. Yamagishi M., Ito K., Tsutsui H., Miyazaki S., Goto Y., Nagaya N., Sumiyoshi T., Fukami K., Haze K., Kitakaze M., Nonogi H., and Tomoike H. Lesion severity and hypercholesterolemia determine long-term prognosis of vasospastic angina treated with calcium channel antagonists. Circ J 67 (2003) 1029-1035
17. Miwa K. Low density lipoprotein particles are small in patients with coronary vasospasm. Int J Cardiol 87 (2003) 193-201
18. Kido S., Ishii Y., Hasebe N., Ido A., Kawashima E., Ogawa Y., Yamashita H., Kikuchi K., and Onodera S. Significance of coronary risk factors and coronary arteriosclerosis for coronary vasospasm. J Cardiol 31 (1998) 135-143
19. Yasue H., Omote S., Takizawa A., Nagao M., Miwa K., and Tanaka S. Circadian variation of exercise capacity in patients with Prinzmetal's variant angina: role of exercise-induced coronary arterial spasm. Circulation 59 (1979) 938-948
20. Poole-Wilson P.A., Lubsen J., Kirwan B.A., van Dalen F.J., Wagener G., Danchin N., Just H., Fox K.A., Pocock S.J., Clayton T.C., Motro M., Parker J.D., Bourassa M.G., Dart A.M., Hildebrandt P., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364 (2004) 849-857
21. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D., Berman L., Shi H., Buebendorf E., Topol E.J., and CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (2004) 2217-2225
22. Sakata K., and Kudo M. Efficacy of benidipine hydrochloride on cardiac event in patients with vasospastic angina without significant coronary artery narrowing: comparison with diltiazem by case control study. Ther Res 24 (2003) 2093-2100 [in Japanese]
23. Uchiyama T., Nozawa K., Wada K., Kan R., and Kobayashi Y. Calcium antagonist and lipid metabolism-effects of benidipine on serum lipids-. Ther Res 14 (1993) 2611-2617 [in Japanese]
24. Takenouchi N., and Oiwa T. Effects of benidipine hydrochloride on serum lipid in hypertensive patients with dyslipidemia. Ther Res 25 (2004) 1591-1598 [in Japanese]
25. Noda H., and Nagamine H. Effects of benidipine hydrochloride (KW-3049) on cardiohemodynamic during exercise in patients with effort angina pectoris. Jpn Pharmacol Ther 18 (1990) S843-S850
26. Kitakaze M., Node K., Minamino T., Asanuma H., Kuzuya T., and Hori M. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 33 (1999) 242-249
27. Yamashita T., Kawashima S., Ozaki M., Rikitake Y., Hirase T., Inoue N., Hirata K., and Yokoyama M. A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens 19 (2001) 451-458
28. Wang N., Minatoguchi S., Chen X.H., Arai M., Uno Y., Lu C., Misao Y., Nagai H., Takemura G., and Fujiwara H. Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase C-dependent nitric oxide in rabbits. J Cardiovasc Pharmacol 43 (2004) 747-757
29. Kita T., Suzuki Y., Eto T., and Kitamura K. Long-term anti-hypertensive therapy with benidipine improves arterial stiffness over blood pressure lowering. Hypertens Res 28 (2005) 959-964
30. Karasawa A., and Kubo K. Calcium antagonisitic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydropyridine derivative, in isolated canine coronary arteries. Jpn J Pharmacol 47 (1988) 35-44
31. Moriyama T., and Karasawa A. Cardiovascular effects of benidipine and amlodipine in isolated tissues and anesthetized dogs. Biol Pharm Bull 17 (1994) 1468-1471
32. Ikeda J., Matsubara M., and Yao K. Effects of benidipine in a rat model for experimental angina. Yakugaku Zasshi 126 (2006) 1377-1381
33. Suzuki H., Yokoyama K., Akimoto Y., and Daida H. Clinical efficacy of benidipine for vasospastic angina pectoris. Arzeim Forsch Drug Res 57 (2007) 20-25